Skip to main content
Clinical Trials/IRCT20190804044429N6
IRCT20190804044429N6RecruitingPhase 2

Efficacy and safety of nasal spray of mometasone 0.05%on olfactory improvement in patients with COVID-19: A randomized, double blind clinical trial

Mazandaran University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR and
  • had an olfactory dysfunction ( reduced or loss of sense of smell) for two weeks

Exclusion Criteria

  • Pregnancy and lactation
  • History of olfactory dysfunction
  • Taking drugs that affect the olfactory disorders
  • Corticosteroids chronic use
  • Nasal anatomic dysfunction
  • Existence of dry ducts or nasal bleeding
  • Existence of herpetic lesion
  • Dissatisfaction with participating in the study

Investigators

Similar Trials